• 1
    Salzman C, Jeste DV, Meyer RE et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry 2008; 69: 889898.
  • 2
    Terasawa K. Kampo. Tokyo: K. K. Standard McIntyre, 1993.
  • 3
    Kim KW, Lee DY, Jhoo JH et al. Diagnostic accuracy of mini-mental status examination and revised hasegawa dementia scale for Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 19: 324330.
  • 4
    Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48 (5 Suppl 6): S10S16.
  • 5
    Okahara K, Ishida Y, Hayashi Y et al. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 532536.
  • 6
    Webber KM, Perry G, Smith MA et al. The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res 2007; 5: 177183.
  • 7
    Webber KM, Casadesus G, Bowen RL et al. Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets 2007; 7: 300303.
  • 8
    Casadesus G, Puig ER, Webber KM et al. Targeting gonadotropins: an alternative option for Alzheimer disease treatment. J Biomed Biotechnol 2006; 2006: doi: 10.1155/JBB/2006/39508.
  • 9
    Hogervorst E, Bandelow S, Combrinck M et al. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol 2004; 39: 16331639.
  • 10
    Holland J, Bandelow S, Hogervorst E. Testosterone levels and cognition in elderly men: a review. Maturitas 2011; 69: 322337.
  • 11
    Rinieris P, Markianos M, Hatzimanolis J et al. A psychoendocrine study in male paranoid schizophrenics with delusional ideas of homosexual content. Acta Psychiatr Scand 1985; 72: 309314.